Comparative therapeutic use of Risedronate and Calcarea phosphorica--allopathy versus homeopathy--in bone repair in castrated rats.
Osteoporosis, a disease characterized by progressive bone loss, has been the target of several studies in the past few years. It results in a much higher risk for fractures and might cause slower bone lesion healing. The aim of this work was to study the effects of Risedronate (allopathic medicine) and Calcarea phosphorica 6CH (homeopathic medicine) on the repair of bone lesions in male rats with osteoporosis induced by castration. Eighty-four three-month-old rats were used divided into four groups of twenty-one animals each. Three groups where castrated and one group was submitted to Sham surgery. One month later, cortical lesions were made in all animals' tibiae and, after one day, the different experimental treatments began according to the following groups: CR--castrated/Risedronate (1 mg/kg/day); CCp--castrated/Calcarea phosphorica 6CH (3 drops/day); CP--castrated/placebo and SP--Sham/placebo. The animals were sacrificed at seven, fourteen and twenty-eight days after the beginning of the treatments and had their tibiae removed. Digital radiographs of the tibiae were taken and analyzed in order to evaluate the optical density of the defect area. Then, they were decalcified and processed for histological and histomorphometrical analysis. The data were submitted to ANOVA, and to the Tukey and Dunnett tests (5%). The allopathic and homeopathic treatments led to different bone formation as regards remodeling and maturation aspects. Further research is necessary to access the resistance and quality of the newly formed bone.
Werkman
Cristina
C
Department of Biosciences and Oral Diagnosis, School of Dentistry of São Jose dos Campos, São Paulo State University.
Senra
Giselle Segnini
GS
da Rocha
Rosilene Fernandes
RF
Brandão
Adriana Aigotti Haberbeck
AA
D000704:Analysis of Variance; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D016723:Bone Remodeling / Q000187:drug effects*; D002130:Calcium Phosphates / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D009919:Orchiectomy; D010024:Osteoporosis / Q000188:drug therapy* / Q000473:pathology; D008517:Phytotherapy; D028321:Plant Preparations; D051381:Rats; D000068296:Risedronic Acid
D050071:Bone Density Conservation Agents; D002130:Calcium Phosphates; D028321:Plant Preparations; D000068296:Risedronic Acid; D012968:Etidronic Acid